Favourites   Have ideas?  Sign in / Register

Positive:   Gene and cell ↓1.92   Medicine ↑0.32   Disease: Central nervous system (CNS) ↑0.32 «See more»   Disease: Neurology/Alzheimer/Parkinson's ↑0.9   Biopharma ↑1.32   Biotechnology ↑5.18

Negative:


Disease: Central nervous system (CNS) segment

CYCN Cyclerion Therapeutics, Inc. - Common Stock 0 + Medicine, Disease: Central nervous system (CNS)

+ My List
PRAX Praxis Precision Medicines, Inc. - Common Stock 4.38% down 12.62% -8.24 + Biopharma, Gene and cell, Disease: Central nervous system (CNS), Medicine


Last highlighted: Research Analysts Set Expectations for Praxis Precision Medicines, Inc.’s Q1 2022 Earnings $PRAX https://t.co/u6zv6m9Tyz #markets
+ My List
RLMD Relmada Therapeutics, Inc. - Common Stock 5.18% 5.18% 0 + Disease: Central nervous system (CNS), Biotechnology, Medicine


Last highlighted: $RLMD 📜 SEC Form 10-Q filed by Relmada Therapeutics, Inc. https://t.co/CGB5BcamVJ 30s delayed. This insight appeared in real-time at 🚆 https://t.co/TvhaBDQJ0C 🚆
+ My List
TNXP Tonix Pharmaceuticals Holding Corp. - Common Stock 0.90% 0.90% 0 + Medicine, Biopharma, Immunology, Disease: Addictions, Disease: Neurology/Alzheimer/Parkinson's, Disease: Central nervous system (CNS)


Last highlighted: $TNXP TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure https://t.co/hFCRf3OmpX
+ My List
TRVN Trevena, Inc. - Common Stock 0 + Biopharma, Medicine, Disease: Central nervous system (CNS)


Last highlighted: $TRVN Trading is easy with Buy and Short signals displayed on the chart https://t.co/optkvg9qmr
+ My List
TSHA Taysha Gene Therapies, Inc. - Common Stock -8.22% down -7.27% -0.95 + Gene and cell, Disease: Central nervous system (CNS), Medicine

+ My List
TTNP Titan Pharmaceuticals, Inc. - Common Stock 0 + Biopharma, Disease: Central nervous system (CNS), Medicine

+ My List


We do not provide financial advice. All displayed data is the result of experiments, and a subjective assessment. All decisions that will be made based on this data are made at your own risk. Thank you for understanding.